Cote d'Ivoire vs Estonia: Access to anti-retroviral drugs, male
Cote d'Ivoire
69.0%
in 2024
Estonia
68.0%
in 2022
Cote d'Ivoire rank
72nd
Estonia rank
73rd
Access to anti-retroviral drugs, male over time
- Cote d'Ivoire
- Estonia
How they compare
Cote d'Ivoire currently reports 69.0% against 68.0% in Estonia, a difference of 1.0%.
Across all 23 years both countries report, Estonia has been ahead every year.
Cote d'Ivoire ranks 72nd and Estonia ranks 73rd of 141 countries.
Estonia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cote d'Ivoire | Estonia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.4% | 9.7% | 6.3% | Estonia |
| 2010s | 28.6% | 53.6% | 25.0% | Estonia |
| 2020s | 57.7% | 68.3% | 10.7% | Estonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Cote d'Ivoire or Estonia?
- Cote d'Ivoire, at 69.0% against 68.0% in Estonia as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Cote d'Ivoire and Estonia?
- 1.0%, with Cote d'Ivoire ahead.
- How many years of comparable data are there for Cote d'Ivoire and Estonia?
- 23 years are reported by both, from 2000 to 2022.
- How do Cote d'Ivoire and Estonia rank globally for access to anti-retroviral drugs, male?
- Cote d'Ivoire ranks 72nd and Estonia ranks 73rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.